Letrozole:: advancing hormone therapy in breast cancer

R.J. Lee; A.C. Armstrong; A.M. Wardley

doi:10.2217/whe.12.49

Letrozole: advancing hormone therapy in breast cancer

R.J. Lee, A.C. Armstrong, A.M. Wardley

Research output: Contribution to journal › Article › peer-review

Abstract

Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, including tamoxifen. Letrozole is well-tolerated, with the main adverse effects reported as hot flushes, arthritis, arthralgia and myalgia, and a trend towards increased risk of fracture.

Original language	English
Pages (from-to)	611-18
Number of pages	7
Journal	Women's Health
Volume	8
Issue number	6
DOIs	https://doi.org/10.2217/whe.12.49
Publication status	Published - 2012

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/whe.12.49

Cite this

@article{45d72a564aed4a34a25f8605d5b2b697,

title = "Letrozole:: advancing hormone therapy in breast cancer",

abstract = "Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, including tamoxifen. Letrozole is well-tolerated, with the main adverse effects reported as hot flushes, arthritis, arthralgia and myalgia, and a trend towards increased risk of fracture.",

author = "R.J. Lee and A.C. Armstrong and A.M. Wardley",

year = "2012",

doi = "10.2217/whe.12.49",

language = "English",

volume = "8",

pages = "611--18",

journal = "Women's Health",

issn = "1745-5057",

publisher = "SAGE Publications Inc.",

number = "6",

}

TY - JOUR

T1 - Letrozole:

T2 - advancing hormone therapy in breast cancer

AU - Lee, R.J.

AU - Armstrong, A.C.

AU - Wardley, A.M.

PY - 2012

Y1 - 2012

N2 - Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, including tamoxifen. Letrozole is well-tolerated, with the main adverse effects reported as hot flushes, arthritis, arthralgia and myalgia, and a trend towards increased risk of fracture.

AB - Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, including tamoxifen. Letrozole is well-tolerated, with the main adverse effects reported as hot flushes, arthritis, arthralgia and myalgia, and a trend towards increased risk of fracture.

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84870439192&partnerID=MN8TOARS

UR - https://www.researchgate.net/publication/233771458_Letrozole_Advancing_hormone_therapy_in_breast_cancer

U2 - 10.2217/whe.12.49

DO - 10.2217/whe.12.49

M3 - Article

SN - 1745-5057

VL - 8

SP - 611

EP - 618

JO - Women's Health

JF - Women's Health

IS - 6

ER -